Big Board Alerts

NICE recommends first immunotherapy treatment for endometrial cancer patients


Jemperli▼ (dostarlimab) has become the first immunotherapy treatment to receive recommendation for use from the National Institute for Health and Care Excellence (NICE), in eligible endometrial cancer patients in a first line setting.

Following the positive recommendation, approximately 580 patients in England, Wales and Northern Ireland could be eligible for treatment with dostarlimab1.

This final draft guidance recommends the use of dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy2.

It is a form of uterine cancer that starts in the lining of the endometrium (womb), is the most common gynaecological cancer in the UK, with rising incidence and mortality rates3,4,5.

Despite advances in medical science, outcomes of advanced and recurrent endometrial cancer remain poor6.
The median overall survival of people with recurrent, advanced endometrial cancer is reported to be less than three years when treated with standard of care platinum-based chemotherapy7.
Based on survival statistics for patients diagnosed between 2013 and 2017 in England, only 15% of people diagnosed with stage 4 disease survive for five years or longer8.

Following the NICE decision, GSK is working with relevant health authorities across the UK, including Scotland, where this medicine is being assessed by the Scottish Medicine Consortium, to try to provide access for those who may benefit from the therapy in this first line setting.

Dr Rebecca Kristeleit, Consultant Medical Oncologist, Guy’s and St Thomas’ NHS Foundation Trust and Adjunct Reader, King’s College London, said: “NICE’s recommendation for use of dostarlimab in combination with chemotherapy in the first line treatment of dMMR endometrial cancer enables access to the first major advance in decades for women with this disease with the potential to significantly improve their survival. This treatment option heralds a new era for biomarker-directed treatment of advanced endometrial cancer.”

Jack Harris, Vice-President UK Oncology, GSK, said: “At GSK, we aspire to get ahead of cancer and improve outcomes for people living with the devastating reality of a diagnosis. Today’s decision is an important step forward, and a testament to our ongoing commitment to driving innovation for people with unmet needs, providing patients with the opportunity to access this treatment in the first line treatment setting. While today’s news is specific to endometrial cancer, our commitment in oncology extends to difficult to treat solid tumours and haematological malignancies. We have seen great developments within our pipeline over the last year and we are proud to have contributed to meaningful advancements in oncology”.


1 GSK Data on file. REF-218017

2 NICE Final Draft Guidance. Data on file. REF-222937

3 NIH. Rising Endometrial Cancer Rates Spur New Approaches to Prevention. Available at: Last accessed March 2024.

4 The Royal Marsden NHS Foundation Trust. Q&A: Gynaecological cancers. Available at: Last accessed March 2024.

5 Cancer Research UK. Uterine cancer statistics. Available at Last accessed March 2024.

6 Oaknin A, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860–877.

7 Mirza MR, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334.

8 Cancer Research UK. Womb cancer survival. Available at: Last accessed March 2024.


Latest Articles


By submitting this form on our website, you agree that we may collect and use your personal information for marketing, and for other purposes as set forth in our privacy policy, which we encourage you to review.